LTR Pharma (ASX:LTP) Ending Cash Position: A$25.78 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
12 GF Score
Price A$0.49
View Full Analysis

What is LTR Pharma Ending Cash Position?

LTR Pharma ASX:LTP -1.02% 12 Ending Cash Position is A$25.78 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 12/100.

LTR Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 was A$25.78 Mil.

LTR Pharma's quarterly Ending Cash Position declined from Dec. 2024 (A$34.07 Mil) to Jun. 2025 (A$31.81 Mil) and declined from Jun. 2025 (A$31.81 Mil) to Dec. 2025 (A$25.78 Mil).

LTR Pharma's annual Ending Cash Position increased from Jun. 2023 (A$1.73 Mil) to Jun. 2024 (A$3.10 Mil) and increased from Jun. 2024 (A$3.10 Mil) to Jun. 2025 (A$31.81 Mil).

LTR Pharma Ending Cash Position Related Terms

LTR Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Ending Cash Position Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
0.15 1.91 1.73 3.10 31.81

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial 6.02 3.10 34.07 31.81 25.78
ASX:LTP
12GF Score
LTR Pharma Ltd ASX:LTP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

LTR Pharma's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.103+28.706
=31.81

LTR Pharma's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=31.809+-6.028
=25.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$25.78 Mil mean?
LTR Pharma (ASX:LTP) has a Ending Cash Position of A$25.78 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Ending Cash Position too high?
LTR Pharma's current Ending Cash Position is A$25.78 Mil. Overall, LTR Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Ending Cash Position compare to VRTX and REGN?
LTR Pharma's Ending Cash Position of A$25.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LTR Pharma and its competitors. LTR Pharma's current Ending Cash Position is A$25.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Ending Cash Position of A$25.78 Mil. The current Ending Cash Position is A$25.78 Mil. LTR Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Ending Cash Position is A$25.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
12GF Score

Get the complete analysis for ASX:LTP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.49
Price